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The rapid diagnosis of septicaemic melioidosis will have an impact on reduction of mortality.
Currently, this relies almost exclusively upon culture of the causative agent Burkholderia
pseudomallei from clinical samples. In acute sepsis, blood is the preferred specimen for culture
and therefore should be the target for a rapid diagnostic tool. A lateral flow immunoassay (LFI)
for the detection of B. pseudomallei antigen has been developed. This was compared with
molecular detection using the targets T3SS1 and IpxO. Forty-five clinical samples of EDTA
blood, which were culture-positive, were tested using both modalities. The LFI had a sensitivity
of 40 %, whilst molecular detection had a sensitivity of 20 %. The poor performance of
molecular detection has been described previously and is largely related to the use of whole-
blood specimens collected into blood tubes containing EDTA. Whilst suboptimal, the LFI would
be an adjunct in the rapid diagnosis of melioidosis.
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INTRODUCTION
Burkholderia pseudomallei is a Gram-negative soil sapro-
phyte which is the aetiological agent of melioidosis. This is
a disease endemic to northern Australia and south-east
Asia, and causes significant morbidity and mortality, with
a wide spectrum of clinical presentations (Malczewski
et al., 2005;White, 2003). The gold standard for the diagnosis
of melioidosis is culture from clinical specimens. This is,
however, time-consuming and may not be easily available
in endemic regions. Serology is of limited value as up to
50 % of blood culture-positive patients are seronegative by
the indirect haemagglutination assay (IHA) at the time of
presentation (Harris et al., 2009). Molecular detection
from clinical samples has been advocated with variable
results. Most targets offer high specificity, but variable
sensitivity (Couto et al., 2009; Kunakorn et al., 2000; Merritt
et al., 2006; Tomaso et al., 2005). False-negative molecular
detection of B. pseudomallei has been attributed to lower
concentrations of the organism in blood (Supaprom et al.,
2007).
Whilst more complex methods, such as genomic transcrip-
tion profiling using microarray technology have shown
greater promise, this technology is generally neither available
nor feasible in regions where this disease is endemic (Pankla
et al., 2009).
The recent development of a prototype lateral flow immu-
noassay (LFI) for antigen detection in melioidosis has
renewed interest in rapid point-of-care testing formelioidosis
(Houghton et al., 2014). In the current study, a LFI prototype
using clinical samples was trialled. Blood from culture-
positive patients admitted with proven melioidosis was used
for LFI and compared with a molecular detection assay
using two different previously described primer sets (T3SS1
cluster and IpxO). Serology using IHA was also performed.
Simple, rapid and reliable diagnostic tests formelioidosis will
help identify cases earlier, leading to improved outcomes,
given that culture and identification of B. pseudomallei
can be delayed for up to 3 days. Furthermore, early
diagnosis and selection of appropriate antimicrobial therapy
help reduce the significant mortality associated with the
disease.
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METHODS
Ethics approval was granted by The Townsville Hospital and Health
Services Ethics Committee (HREC/14/QTHS/13).
Clinical samples. In total, 45 clinical specimens from 30 patients
were collected on admission and stored at 270 uC. The 45 EDTA
whole-blood samples were collected before, after or at the same time
as specimens collected which were subsequently culture-positive for
B. pseudomallei. All specimens were thawed and used as detailed
below. EDTA blood samples which subsequently cultured Pseudo-
monas aeruginosa, coagulase-negative Staphylococcus, Escherichia coli
or an unidentified Gram-negative bacillus (not B. pseudomallei) were
used as negative controls.
LFI. The InBios Active Melioidosis Detect test is a membrane
immunoassay designed to detect soluble capsular polysaccharide from
B. pseudomallei in a range of sample types (Houghton et al., 2014).
For use with whole blood, 35 ml of specimen was added to the lateral
flow strip under the indicator arrow. The strip was then transferred to
a well loaded with chase buffer and the results recorded after 15 min.
A positive, valid test was indicated by the presence of a red line in
both the test and control regions.
Molecular detection. Quantitative real-time (qRT)-PCR was per-
formed on the 45 clinical culture-positive samples, along with four
controls using previously described molecular targets T3SS1 and IpxO
and protocols (Kaestli et al., 2012; Merritt et al., 2006; Meumann
et al., 2006).
Serology. The IHA was performed as described previously (Gilmore
et al., 2007) using sera collected at the same time as the positive blood
cultures. A positive IHA was defined as a titre of i1 : 40.
RESULTS AND DISCUSSION
Of the 45 EDTA blood samples, 27 were collected on the
same day as the positive blood culture. Four were collected
1–7 days before and 14 were collected 1–4 days after collec-
tion of the positive blood culture. These specimens had
been stored at 270 uC for up to 72 months. The four con-
trol samples used in the study tested negative by both the
LFI and molecular detection.
The results for LFI, T3SS1, IpxO PCRs and IHA are given in
Table 1. These include the time frame (days) when the
sample was collected in relation to the sample that yielded
a positive B. pseudomallei culture. There were a total of 16
positive LFIs (40 %, 16/40) with five indeterminate assays.
The indeterminate assays were due to the non-appearance
of the control line and were probably related to a lack of
sample flow. We did not repeat these due to a limited
number of available LFI strips.
There were nine positive PCR results (20 %, 9/45). These
included either or both targets used. When compared
with culture, the LFI had a sensitivity of 40 % and the com-
bined PCR targets had a sensitivity of 20 %. A summary of
the yields of these diagnostic approaches based on the time
difference between culture positivity and blood sample col-
lection is given in Table 2.
The early diagnosis of melioidosis currently relies upon the
culture and correct identification of B. pseudomallei from
Table 1. Comparison of the LFI with molecular detection and
IHA
Sample ID LFI qRT-PCR IHA Collection of sample
relative to day of
positive blood culture*T3SS1 IpxO
3 + + + 5 +2
6 + + – ,5 +2
8 + 2 2 ,5 +2
11 + 2 2 10 0
12 + 2 2 80 0
16 + 2 2 320 0
17 + 2 2 ,5 21
19 + 2 2 ,5 0
24 + 2 2 640 23
25 + + 2 ,5 1+
26 + 2 2 ,5 0
30 + + + ,5 27
37 + 2 2 1280 +1
38 + + + ,5 +1
39 + + + ,5 0
40 + 2 2 ,5 23
2 IND 2 2 5 0
7 IND 2 2 ,5 +1
9 IND 2 2 ,5 2
15 IND + + 320 0
18 IND 2 2 ,5 0
1 2 2 2 5 0
4 2 2 2 5 +1
5 2 2 2 ,5 +4
10 2 2 2 .5120 0
13 – – – ,5 0
14 2 2 2 ,5 0
20 2 2 2 160 +2
21 2 + + 160 +2
22 2 2 2 160 +1
23 2 2 2 160 0
27 2 2 2 20 +2
28 2 2 2 20 +1
29 2 2 2 20 +2
31 2 2 2 40 0
32 2 2 2 ,5 2+
33 2 2 2 5 0
34 2 2 2 ,5 0
35 2 2 2 ,5 +2
36 2 2 2 80 0
41 2 2 2 ,5 0
42 2 2 2 ,5 0
43 2 2 2 ,5 0
44 2 + + ,5 +1
45 2 2 2 ,5 0
Control 2 2 2 NA NA
Control 2 2 2 NA NA
Control 2 2 2 NA NA
Control 2 2 2 NA NA
IND, indeterminate; NA, not applicable;*, blood sample collected on
the same day as sample that yielded a positive B. pseudomallei culture;
+, sample collected n days after the sample that yielded a positive cul-
ture; 2, sample collected n days before the sample that yielded a posi-
tive culture.
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clinical samples. Bacteraemic melioidosis carries a greater
mortality than non-bacteraemic disease. Whilst previous
studies have shown that molecular or antigen detection
of B. pseudomallei from sputum or urine can be an effective
diagnostic modality (Ekpo et al., 2007; Meumann et al.,
2006; Pongsunk et al., 1999), direct detection from blood
remains problematic. The sensitivity of direct PCR detec-
tion of B. pseudomallei from blood has been reported to
vary from 31 (Kunakorn et al., 2000) to 56 % (Meumann
et al., 2006). One of these studies suggested that EDTA
plasma was superior to EDTA blood for PCR assays
(Richardson et al., 2012). The primers chosen (T3SS1
and IpxO) are well described and used routinely in the
molecular confirmation of isolates. Their poor perform-
ance here may relate to the samples used. It is acknowl-
edged that further work in determining ideal primer sets
for the detection of B. pseudomallei from EDTA blood is
warranted.
The development of the LFI has provided an opportunity to
assess a new rapid diagnostic test for melioidosis. This study
has shown that this assay may have a role as an adjunct in
early diagnosis of melioidosis. It performed better than
bothmolecular targets used. There was no difference in posi-
tivity related to the age of the specimen. Specimens from
2008 were just as likely to be positive as more recent speci-
mens from 2014. Although the numbers were small, the
LFI appeared to perform better with blood that had been col-
lected 1–7 days prior to the collection of blood cultures that
subsequently yielded positive cultures. It is likely that this
reflects a lack of clinical recognition that the patient was sep-
ticaemic at the time, with the failure to collect blood cultures
accordingly.
We used four negative controls of blood collected from
patients with bacteraemias. These included blood that sub-
sequently cultured E. coli, coagulase-negative Staphylococcus,
P. aeruginosa and an unidentified Gram-negative bacillus.
The reason for this choice was to try to cover a range of
organisms seen in a diagnostic laboratory. We specifically
chose an unidentified Gram-negative bacillus to ‘blind’ the
process. Although increasing the number of negative con-
trols would have been ideal, we were limited by the
number of LFI strips available for this work. We were
unable to obtain sera from a patient with the closely related
Burkholderia cepacia bacteraemia because of the rarity of this
condition.
A comparison was also made with the IHA performed on
blood collected at the same time as the clinical specimens
that were culture-positive. A total of 12 (40 %) patients of
the 30 culture-positive patients were IHA-positive. Of the
16 LFI-positive samples, only four (25 %) were IHA-posi-
tive. Of the nine qRT-PCR (either T3SS1 or Ipxo)-positive,
only two (22 %) were IHA-positive as well. This highlights
the poor utility of the IHA as a diagnostic test formelioidosis
(Harris et al., 2009). There was little difference in IHA posi-
tivity between the LFI-positive samples based on time of col-
lection (Table 2).
The main limitations of this study include the length of sto-
rage of the specimens used in the study and the limited
number of samples. Another limitation was the exclusion
of specimens other than EDTA whole blood, such as urine
or sputum. This was done deliberately to simulate the clinical
situations where septic patients require urgent diagnosis of
bacteraemia. We specifically excluded urine and sputum to
mimic this situation of severe sepsis where blood cultures
are routinely collected. In contrast, urine may be negative
if the source was not urinary, and sputum can be difficult
to collect in this group. It was also decided not to use
enriched blood cultures as this would introduce a delay in
diagnosis. Nevertheless, this could be an aspect of rapid diag-
nosis of suspected melioidosis when a blood culture has sig-
nalled positive with Gram-negative bacilli in an endemic
region.
This study examined the utility of the LFI as a rapid diagnos-
tic tool. It performed better than molecular detection from
blood. The early detection of sepsis due to B. pseudomallei
remains an elusive goal. The development of the LFI provides
a possible alternative.
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